These results indicate that although the single-dose HA-CXCL13-circRNA provided complete protection against homologous influenza virus infection and 90% protection against heterologous influenza virus infection, there is still a low-risk infection when facing heterologous influenza virus compared to the two-dose regimen. The gene discussed is CXCL13; the disease is infection.